CY1117507T1 - COMPOSITION FOR SUSPENSION - Google Patents

COMPOSITION FOR SUSPENSION

Info

Publication number
CY1117507T1
CY1117507T1 CY20151100923T CY151100923T CY1117507T1 CY 1117507 T1 CY1117507 T1 CY 1117507T1 CY 20151100923 T CY20151100923 T CY 20151100923T CY 151100923 T CY151100923 T CY 151100923T CY 1117507 T1 CY1117507 T1 CY 1117507T1
Authority
CY
Cyprus
Prior art keywords
compositions
suspension
composition
proteasome inhibitors
cyclodextrin
Prior art date
Application number
CY20151100923T
Other languages
Greek (el)
Inventor
Evan R Lewis
Mark Nguyen Ho
Fabiana N Fonseca
Original Assignee
Onyx Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10179422.0A external-priority patent/EP2261236B1/en
Application filed by Onyx Therapeutics, Inc. filed Critical Onyx Therapeutics, Inc.
Publication of CY1117507T1 publication Critical patent/CY1117507T1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Οι συνθέσεις που περιλαμβάνουν έναν ή περισσότερους αδιάλυτους πρακτικά αναστολείς πρωτεασώματος και κυκλοδεξτρίνη, ιδιαίτερα μια υποκατεστημένη κυκλοδεξτρίνη, ουσιαστικά αυξάνουν τη διαλυτότητα αυτών των αναστολέων πρωτεασώματος και διευκολύνουν τη χορήγηση τους. Αυτές οι συνθέσεις περιλαμβάνουν προαιρετικά ένα ρυθμιστικό. Οι μέθοδοι θεραπευτικής αντιμετώπισης χρησιμοποιώντας αυτές τις συνθέσεις κοινοποιούνται επίσης.Compositions comprising one or more practically insoluble proteasome inhibitors and cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. These compositions optionally include a buffer. Methods of treatment using these compositions are also disclosed.

CY20151100923T 2004-12-07 2015-10-15 COMPOSITION FOR SUSPENSION CY1117507T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63436604A 2004-12-07 2004-12-07
US65593005A 2005-02-23 2005-02-23
EP10179422.0A EP2261236B1 (en) 2004-12-07 2005-12-07 Composition for proteasome inhibition

Publications (1)

Publication Number Publication Date
CY1117507T1 true CY1117507T1 (en) 2017-04-26

Family

ID=58449087

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100432T CY1114025T1 (en) 2004-12-07 2013-05-30 COMPOSITION FOR SUSPENSION
CY20151100923T CY1117507T1 (en) 2004-12-07 2015-10-15 COMPOSITION FOR SUSPENSION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100432T CY1114025T1 (en) 2004-12-07 2013-05-30 COMPOSITION FOR SUSPENSION

Country Status (1)

Country Link
CY (2) CY1114025T1 (en)

Also Published As

Publication number Publication date
CY1114025T1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
CY1111489T1 (en) COMPOUNDS FOR SUSPENSION
NO2020031I1 (en) cobimetinib, including pharmaceutically acceptable salts and solvates, in particular cobimetinib hemifumarate
CY1116693T1 (en) A combination of azelastin and cycloneside
CY1113192T1 (en) UNIONS AND METHODS FOR THE SUSPENSION OF SUSPENSION PROGRESS THROUGH AURORA SUSPENSION
EA200701065A1 (en) INJECTABLE COMPOSITIONS CONTAINING NANODISPERS Olanzapine
CY1116272T1 (en) PHARMACEUTICAL PARTICLES CONTAINING METHYLNALTREXON
CY1113963T1 (en) PHARMACEUTICAL COMPOSITIONS WHICH INCLUDE ACTIVIA-COMPETITORS AND USE THESE IN PREVENTION OR MULTIPLE
NO20081554L (en) Isoindollide compounds and compositions comprising the same, and their use
CY1106679T1 (en) AZADICYCLIC HETEROCYCLIC COMPOUNDS AS CANNABINOID RECEPTOR MODIFIERS
MXPA05013977A (en) Methods and compositions for treating amyloid-related diseases.
EA200501928A1 (en) Pyrrolodihydroisoquinols as inhibitors of PDE10
CY1109916T1 (en) Benzimidazolo-thiophene compounds as PLK inhibitors
CY1111983T1 (en) PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF ANTIFICIAL AGENT IN COMBINATION
CY1109465T1 (en) NEW PHARMACEUTICAL MEDICINES FORMONTAFINILIS
CY1112591T1 (en) FROM THE ORAL PHARMACEUTICAL FORMS OF CLANDRIVIN
EA200801414A1 (en) CALCYLYTIC COMPOUNDS
EA200601596A1 (en) IMPROVED 6-MERCAPTOPURIN COMPOSITION
NO20063293L (en) Pharmaceutical compounds
CY1117507T1 (en) COMPOSITION FOR SUSPENSION
CY1114113T1 (en) COMBINATION OF A VASCULAR IF VASCULAR INHIBITOR AND A BETA-INHIBITOR
CY1114373T1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING DROCHIDORA
CY1114328T1 (en) AMINOCINOLONES AS GSK-3 INHIBITORS
CY1114807T1 (en) 2,4-Pyrimidinodiamine Compounds for Therapeutic Treatment or Prevention of Autoimmune Diseases
CY1114511T1 (en) CARBONYLAMINE PYRROLOPYRAZOLES, POSSIBLE CHINASE INHIBITORS